Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Avalo Therapeutics Inc.
Headquarters: Rockville, MD, United States of America
Website: http://www.avalotherapeutics...
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Garry Arthur Neil, MD
Number Of Employees: 19
Enterprise Value: $-985,684
PE Ratio: -0.04
Exchange/Ticker 1: NASDAQ:AVTX
Exchange/Ticker 2: N/A
Latest Market Cap: $77,639,904
BioCentury | Jan 4, 2025
Management Tracks
Four companies announce new CFOs
Plus: Jia joins Grit Bio and Riley joins Avalo
BioCentury | Apr 2, 2024
Deals
Deals report: Abingworth and Blackstone bet on late-stage programs
Plus: Gilead acquires Xilio’s IL-12 program and Harmonic-Turbine to co-develop dark kinase therapy for cancer
BioCentury | Mar 29, 2024
Finance
Public equity report: Avalo gets makeover with PIPE, acquisition
Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons
BioCentury | Aug 17, 2023
Emerging Company Profile
How Abcuro is targeting specific T cells to treat a rare muscle-wasting disease
Crossovers back company in $155M round to advance KLRG1 program for inclusion body myositis
BioCentury | Jun 16, 2022
Management Tracks
Dealhoy becomes CBO at Deciphera
Plus new CSO at GlycoEra, and updates from Geron, Ysios, CBC and more
BioCentury | Feb 18, 2022
Management Tracks
Nelson, Collins to fill void left by Lander at White House
Plus Clayton joins Horizon as EVP, general counsel and updates from Ribon, Leo and more
BioCentury | Jan 13, 2022
Management Tracks
Carino joins White House’s office of science and technology policy
Plus Foster becomes venture partner and updates from Norwest, TCR2, PTC and more
BioCentury | Aug 28, 2021
Product Development
Aug. 27 Quick Takes: BioMarin gains first worldwide approval for achondroplasia therapy
Plus: Roche’s Tecentriq withdrawal, a16z’s seed fund, Lynk’s venture round and more
Items per page:
1 - 8 of 8